MX369840B - Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. - Google Patents

Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.

Info

Publication number
MX369840B
MX369840B MX2016010912A MX2016010912A MX369840B MX 369840 B MX369840 B MX 369840B MX 2016010912 A MX2016010912 A MX 2016010912A MX 2016010912 A MX2016010912 A MX 2016010912A MX 369840 B MX369840 B MX 369840B
Authority
MX
Mexico
Prior art keywords
novel
oxazolo
pyrazine
dihydro
compounds
Prior art date
Application number
MX2016010912A
Other languages
English (en)
Other versions
MX2016010912A (es
Inventor
Luiz Sacurai Sérgio
Eduardo Da Costa Touzarim Carlos
Travanca Toledo Fabiano
Artur De Sousa Bruno
Original Assignee
Biolab Sanus Farmaceutica Ltda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biolab Sanus Farmaceutica Ltda filed Critical Biolab Sanus Farmaceutica Ltda
Publication of MX2016010912A publication Critical patent/MX2016010912A/es
Publication of MX369840B publication Critical patent/MX369840B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/04—Drugs for disorders of the urinary system for urolithiasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a nuevos derivados de 6,7-dihidro-3H-oxazolo[3,4-a]pirazina-5,8-diona o a una mezcla de éstos. La presente invención también contempla composiciones farmacéuticas que comprendan una cantidad eficaz de uno de los nuevos compuestos que son objeto de la presente invención, así como el uso de dichos compuestos y/o derivados como inhibidores de enzimas fosfodiesterasas y el uso de los compuestos y/o derivados en el tratamiento de la disfunción eréctil, de trastornos y/o condiciones tratables con relajación de tejidos y de trastornos tratables con inhibidores de fosfodiesterasas, más específicamente con inhibidores de la PDE-5. Un objetivo adicional de la presente invención es proveer un medicamento que comprenda una cantidad terapéuticamente eficaz de uno de los nuevos compuestos y un método de tratamiento utilizando dichos nuevos compuestos.
MX2016010912A 2014-02-24 2015-02-24 Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona. MX369840B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461943825P 2014-02-24 2014-02-24
PCT/BR2015/000023 WO2015123748A1 (pt) 2014-02-24 2015-02-24 "NOVOS COMPOSTOS DERIVADOS DE 6,7-DIHIDRO-3H-OXAZOLO [3,4-a] PIRAZINA-5,8-DIONA "

Publications (2)

Publication Number Publication Date
MX2016010912A MX2016010912A (es) 2016-11-30
MX369840B true MX369840B (es) 2019-11-22

Family

ID=53877456

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010912A MX369840B (es) 2014-02-24 2015-02-24 Nuevos compuestos derivados de 6, 7-dihidro-3h-oxazolo [3, 4-a] pirazina-5, 8-diona.

Country Status (19)

Country Link
US (1) US9359378B2 (es)
EP (1) EP3133072B1 (es)
JP (1) JP6636463B2 (es)
KR (1) KR102408431B1 (es)
AR (1) AR099523A1 (es)
AU (1) AU2015221431B2 (es)
BR (1) BR112016019609B1 (es)
CA (1) CA2940225C (es)
CL (1) CL2016002125A1 (es)
ES (1) ES2734063T3 (es)
HU (1) HUE044993T2 (es)
IL (1) IL247330B (es)
MX (1) MX369840B (es)
PL (1) PL3133072T3 (es)
PT (1) PT3133072T (es)
TR (1) TR201910896T4 (es)
UY (1) UY36010A (es)
WO (1) WO2015123748A1 (es)
ZA (1) ZA201606522B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114158266A (zh) * 2019-07-15 2022-03-08 生物实验萨纽斯药物有限公司 化合物3-(苯并[d][1,3]二氧杂环戊烯-5-基)-7-(1-羟基丙-2-基)-1-(1H-吲哚-3-基)-6,7-二氢-3H-噁唑并[3,4-a]吡嗪-5,8-二酮的立体异构体及其作为抗肿瘤剂和磷酸二酯酶抑制剂的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA03011082A (es) * 2001-06-05 2004-07-08 Lilly Icos Llc Derivados de pirazino-1',2': 1,6-prirido-3,4-b-indol-1,4-diona.
AR045950A1 (es) * 2003-10-09 2005-11-16 Speedel Experimenta Ag Compuestos derivados de piperazina, composiciones farmaceuticas que los contienen y su uso en la fabricacion de medicamentos.
AR073522A1 (es) * 2008-09-30 2010-11-10 Biolab Sanus Farmaceutica Ltda Compuestos derivados de 2-(3-metilenodioxi) - benzoil indol
BRPI0903803B1 (pt) * 2009-09-30 2019-07-09 Biolab Sanus Farmacêutica Ltda. Composto, processo de preparação, composição farmacêutica e uso dos compostos
UY33535A (es) * 2010-08-13 2011-12-01 Biolab Sanus Farmaceutuca Limitada Derivados de 6,7-dihidro-3h-oxazolo[3,4]pirazin-5,8-diona

Also Published As

Publication number Publication date
AU2015221431A1 (en) 2016-09-29
IL247330A0 (en) 2016-09-29
WO2015123748A1 (pt) 2015-08-27
PL3133072T3 (pl) 2019-10-31
US9359378B2 (en) 2016-06-07
IL247330B (en) 2020-10-29
AU2015221431A8 (en) 2016-11-24
AR099523A1 (es) 2016-07-27
CA2940225C (en) 2021-12-28
UY36010A (es) 2015-09-30
HUE044993T2 (hu) 2019-11-28
EP3133072A1 (en) 2017-02-22
JP6636463B2 (ja) 2020-01-29
JP2017506263A (ja) 2017-03-02
EP3133072B1 (en) 2019-05-01
ZA201606522B (en) 2018-04-25
CA2940225A1 (en) 2015-08-27
CL2016002125A1 (es) 2016-12-30
KR102408431B1 (ko) 2022-06-13
BR112016019609A2 (es) 2017-08-22
AU2015221431B2 (en) 2018-04-19
MX2016010912A (es) 2016-11-30
US20150239903A1 (en) 2015-08-27
EP3133072A4 (en) 2017-08-09
KR20160116028A (ko) 2016-10-06
BR112016019609B1 (pt) 2022-06-14
PT3133072T (pt) 2019-07-26
TR201910896T4 (tr) 2019-08-21
ES2734063T3 (es) 2019-12-04

Similar Documents

Publication Publication Date Title
MX2023004037A (es) Compuestos biciclicos como inhibidores alostericos de shp2.
PH12019500521A1 (en) Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer
MX2019003790A (es) Analogos de isoxazol como agonistas de fxr y metodos de uso de los mismos.
PH12017500941A1 (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
EA202091709A1 (ru) Ингибиторы днк-пк
NZ770222A (en) Bicyclic lactams and methods of use thereof
MX2017017097A (es) Macrociclos diarílicos quirales como moduladores de proteínas quinasas.
MY192717A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MY193524A (en) Diaryl macrocycles as modulators of protein kinases
EA202091708A1 (ru) Ингибиторы днк-пк
EP2576549A4 (en) Bicyclic Heteroarylkinase Inhibitors and Methods of Use
PH12017500841B1 (en) 2-amino-6-(difluoromethyl)- 5,5-difluoro-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
MX2017004618A (es) Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades.
PH12017501043A1 (en) 2-amino-5,5-difluoro-6-(fluoromethyl)-6-phenyl-3,4,5,6-tetrahydropyridines as bace1 inhibitors
EA033238B1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
MX2018012902A (es) Composiciones y métodos para el tratamiento de trastornos de almacenamiento lisosomal y trastornos caracterizados por disfunción lisosomal.
MX2019006863A (es) Inhibidores de heparanasa y uso de los mismos.
PH12017502260A1 (en) Tricyclic compounds and their use as phosphodiesterase inhibitors
MX2017013137A (es) Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas.
PH12017500595B1 (en) Aldosterone synthase inhibitors
PH12017500089B1 (en) Aldosterone synthase inhibitors
MX2018007517A (es) Compuestos triciclicos y composiciones como inhibidores de quinasa.
MX2019014272A (es) Compuestos policiclicos y usos de los mismos.

Legal Events

Date Code Title Description
FG Grant or registration